SCHEMBL3857263

SCHEMBL3857263

Cc1ccc(CN(C=O)C2CCC(CN(Cc3cccc(F)c3F)S(=O)(=O)c3ccccc3C(F)(F)F)CC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 7/20 0.39
DPP4 P27487 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
NPY1R P25929 2/20 0.34
NPY5R Q15761 2/20 0.34
STAT3 P40763 1/20 0.34
STAT1 P42224 1/20 0.34
RORC P51449 1/20 0.33
RAB9A P51151 1/20 0.33
KCNA5 P22460 1/20 0.33
ESR2 Q92731 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3855964 0.88 TAS2R14 (0.50) TAS2R14DPP4DPP8DPP9DPP7
SCHEMBL3852960 0.88 TAS2R14 (0.49) TAS2R14CNR1CNR2KCNA5
SCHEMBL3861362 0.84 TAS2R14 (0.52) TAS2R14CNR1CNR2KCNA5
SCHEMBL3856124 0.81 TAS2R14 (0.47) TAS2R14CNR1CNR2STAT3STAT1
SCHEMBL3854326 0.81 TAS2R14 (0.52) TAS2R14CNR1CNR2STAT3MEN1
SCHEMBL3859021 0.80 TAS2R14 (0.50) TAS2R14CNR1CNR2KCNA5TDP1
SCHEMBL3850294 0.79 TAS2R14 (0.51) TAS2R14CNR1CNR2KCNA5
SCHEMBL3857266 0.79 DPP4 (0.39) TAS2R14DPP4DPP8DPP9DPP7
SCHEMBL3853179 0.78 TAS2R14 (0.52) TAS2R14CNR1CNR2KCNA5TDP1
SCHEMBL3856885 0.77 TAS2R14 (0.51) TAS2R14DPP4DPP9DPP7CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579504-B2 ABCA1 elevating compounds GILEAD SCIENCES, INC. (US) 2009-08-25 US claimed
US-20070203245-A1 ABCA1 elevating compounds CV THERAPEUTICS, INC. 2007-08-30 US claimed
US-7579504-B2 ABCA1 elevating compounds GILEAD SCIENCES, INC. (US) 2009-08-25 US disclosed
US-20070203245-A1 ABCA1 elevating compounds CV THERAPEUTICS, INC. 2007-08-30 US disclosed
WO-2007067817-A1 ABCA1 ELEVATING COMPOUNDS CV THERAPEUTICS, INC. (US) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203245-A1 ABCA1 elevating compounds ABCD3, ABCB4, CETP TAS2R14 4736/4885DPP4 1111/4885DPP8 1207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.